There is   no established public trading market for the Pre-Funded Warrants, the   Warrants or Series B Preferred Stock, and we do not expect a market to   develop.The number of shares of Common Stock outstanding after the offering is based on 19,426,163 shares outstanding as of March 31, 2018, and excludes as of such date:·1,118,849 shares of Common Stock issuable upon the exercise of stock options outstanding at March 31, 2018 with a weighted average exercise price of approximately $25.00 per share;·15,232,146 shares of Common Stock issuable upon the exercise of outstanding or issuable warrants at March 31, 2018 with a weighted average exercise price of approximately $1.82 per share (includes Common Stock issuable for warrants which are exercisable for our Series A Convertible Preferred Stock, which is convertible to Common Stock); to the extent the preferred stock warrant repricing described under “Underwriting – Company Lock-up Waiver Agreement” occurs, preferred stock warrants to purchase an aggregate of 994,750 shares of our Series A Convertible Preferred Stock, which are convertible into an aggregate of 9,947,500 shares of Common Stock, will be repriced, and the weighted average exercise price of all outstanding or issuable warrants at March 31, 2018 taking into account such repricing will be approximately $1.46 per share based on an assumed public offering price per Unit of $0.46, the last reported sale price of Common Stock on the Nasdaq Capital Market on April 25, 2018;·0 shares of Common Stock issuable upon the conversion of our Series A Convertible Preferred Stock at March 31, 2018 (no shares of Series A Preferred Stock were issued and outstanding and 1,044,488 shares of Series A Preferred Stock were reserved for issuance upon the exercise of outstanding preferred stock warrants as of March 31, 2018);·33,779 shares of Common Stock reserved for future issuance under our 2013 Equity Compensation Plan at March 31, 2018; and·any additional shares of Common Stock that we may issue to Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to a purchase agreement we entered into on October 8, 2015, which provides that, upon the terms and subject to the conditions and limitation set forth therein, Lincoln Park is committed to purchase up to an aggregate of an additional $15 million of shares of Common Stock over the term of the purchase agreement, should we elect to sell shares to Lincoln Park.As of April 20, 2018, the total number of our outstanding shares of Common Stock was 20,243,108.Unless otherwise indicated, all information contained in this prospectus assumes (i) no exercises by the underwriter of its option to purchase additional securities and (ii) no sale of any Pre-Funded Warrants.10Table of ContentsRISK FACTORSOur business is influenced by many factors that are difficult to predict, and that involve uncertainties that may materially affect actual operating results, cash flows and financial condition.
Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus and in documents incorporated by reference herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this prospectus.Actual results could differ materially and adversely from our forward-looking statements due to a number of factors, including, without limitation, risks related to:·our need for additional financing for our INSPIRE trial and other operations, and our ability to obtain sufficient funds on acceptable terms when needed, and our plans and future needs to scale back operations if adequate financing is not obtained;·our ability to continue as a going concern;·our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;·the success and timing of our preclinical studies and clinical trials, including site initiation and patient enrollment, and regulatory approval of protocols for future clinical trials;·our ability to enter into, maintain and perform collaboration agreements with other pharmaceutical companies, for funding and commercialization of our clinical drug product candidates or preclinical compounds, and our ability to achieve certain milestones under those agreements;·the difficulties in obtaining and maintaining regulatory approval of our product candidates, and the labeling under any approval we may obtain;·our plans and ability to develop, manufacture and commercialize our product candidates;·our failure to recruit or retain key scientific or management personnel or to retain our executive officers;14Table of Contents·the size and growth of the potential markets for our product candidates and our ability to serve those markets;·regulatory developments in the United States and foreign countries;·the rate and degree of market acceptance of any of our product candidates;·obtaining and maintaining intellectual property protection for our product candidates and our proprietary technology;·the successful development of our commercialization capabilities, including sales and marketing capabilities;·recently enacted and future legislation and regulation regarding the healthcare system;·the success of competing therapies and products that are or may become available;·our ability to maintain the listing of our securities on a national securities exchange;·the potential for third party disputes and litigation; and·the performance of third parties, including contract research organizations and third-party manufacturers.Any forward-looking statements that we make in this prospectus and the documents incorporated by reference herein speak only as of the date of such statement, and we undertake no obligation to update such statements whether as a result of any new information, future events, changed circumstances or otherwise.
We believe this data is accurate in all material respects as of the date of this prospectus.15Table of ContentsUSE OF PROCEEDSWe estimate that the net proceeds to us from this offering will be approximately $22.2 million, based on an assumed public offering price per Unit of $0.46, the last reported sale price of Common Stock on the Nasdaq Capital Market on April 26, 2018, assuming the sale of 54,347,826 Units and no sale of any Pre-Funded Units in this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of Warrants issued pursuant to this offering.
If the underwriter exercises its option to purchase the additional Units in full, we estimate that the net proceeds will be approximately $26.0 million, based on an assumed public offering price per Unit of $0.46, the last reported sale price of Common Stock on the Nasdaq Capital Market on April 25, 2018, assuming the sale of 62,500,000 Units and no sale of any Pre-Funded Units in this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the Warrants issued pursuant to this offering.We intend to use the net proceeds from this offering to fund the development of our clinical and preclinical programs, for other research and development activities and for general corporate purposes, which may include capital expenditures and funding our working capital needs.